Clinical trial
A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Albiglutide for the Treatment of Type 2 Diabetes Mellitus in Pediatric Patients
NCT03015519 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Albiglutide for the Treatment of Type 2 Diabetes Mellitus in Pediatric Patients
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Withdrawn
- Start date
- August 14, 2017
- Completion date
- April 20, 2020
- Enrollment
- 0 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.